• Chart
  • F&O
  • Rating
  • Financials
  • Technicals
  • Volume
  • Result
  • Synopsis
  • Corp Action
  • MF Shareholding
  • Similar Stocks
  • FAQs
    1. Home
    2. Stocks
    3. Auropharma Share Price

    Aurobindo Pharma Share PriceAurobindo Pharma

    Large Cap 11.7k Result
    ₹1,021.5
    • Advice
    • Hold
    As on 30 November, 2023 | 09:12 BSE: 524804 NSE: AUROPHARMAISIN: INE406A01037

    Aurobindo Pharma Performance

    Day Range

    • Low 0.00
    • High 0.00
    ₹ 1,021.5

    52 Week Range

    • Low 0.00
    • High 1,058.00
    ₹ 1,021.5
    • Open Price1,021.50
    • Previous Close1,021.45
    • Volume1848

    Start SIP in Aurobindo Pharma

    Start SIP

    Aurobindo Pharma Share Price

    • Over 1 Month 19.54%
    • Over 3 Month 23.24%
    • Over 6 Month 67.09%
    • Over 1 Year 118.91%

    Aurobindo Pharma Key Statistics

    P/E Ratio 25.7
    PEG Ratio 2.5
    Market Cap Cr 59,854
    Price to Book Ratio 2.2
    EPS 20.8
    Dividend 0.6
    Relative Strength Index 65.52
    Money Flow Index 78.21
    MACD Signal 33.74
    Average True Range 26.28

    Aurobindo Pharma F&O

    Aurobindo Pharma Futures
    Aurobindo Pharma Option Chain

    Aurobindo Pharma Investment Rating

    • Master Rating:

    • Aurobindo Pharma has an operating revenue of Rs. 26,950.03 Cr. on a trailing 12-month basis. An annual revenue growth of 6% is not great, Pre-tax margin of 11% is healthy, ROE of 7% is fair but needs improvement. The company has a reasonable debt to equity of 2%, which signals a healthy balance sheet. The stock from a technical standpoint is comfortably placed above its key moving averages, around 11% and 41% from 50DMA and 200DMA. It has recently broken out of a base in its weekly chart and is trading around 9% from the pivot point (which is extended from the ideal buying range for a stock). From an O'Neil Methodology perspective, the stock has an EPS Rank of 63 which is a FAIR score but needs to improve its earnings, a RS Rating of 84 which is GOOD indicating the outperformance as compared to other stocks, Buyer Demand at A which is evident from recent demand for the stock, Group Rank of 69 indicates it belongs to a poor industry group of Medical-Generic Drugs and a Master Score of B is close to being the best. Institutional holding has gone up in the last reported quarter is a positive sign. Overall, the stock is lagging behind in earnings parameter, but excellent technical strength makes it a stock to examine in more detail.

    EPS Strength

    Price Strength

    Buyer Demand

    Group Rank

    Aurobindo Pharma Financials
    IndicatorSep 2023Jun 2023Mar 2023Dec 2022Sep 2022Jun 2022Mar 2022
    Oper Rev Qtr Cr 2,6482,3643,4843,4182,9702,7352,878
    Operating Expenses Qtr Cr 2,1241,9682,8562,9592,7302,5452,380
    Operating Profit Qtr Cr 545422692473296242507
    Depreciation Qtr Cr 6660115109109103101
    Interest Qtr Cr 373249391985
    Tax Qtr Cr 130901711065948-63
    Net Profit Qtr Cr 416336645299165122802
    IndicatorMar 2023Mar 2022
    Total Revenue Annual Cr 13,22611,958
    Operating Expenses Annual Cr 11,0619,814
    Operating Profit Annual in Cr 1,7311,473
    Depreciation Cr 435415
    Interest Annual Cr 11517
    Tax Annual Cr 384183
    Net Profit Annual Cr 1,2301,455
    IndicatorMar 2023Mar 2022
    Cash from Operating Activity Annual Cr 1,8213,727
    Cash from Investing Activity Annual Cr -3,460-1,614
    Cash from Financing Annual Activity Cr 1,719-2,448
    Net Cash Flow Annual Cr 81-334
    IndicatorMar 2023Mar 2022
    Total ShareHolders Funds Annual Cr 17,91417,117
    Fixed Assets Annual Cr 3,9273,811
    Total Non Current Assets Annual Cr 15,21011,766
    Total Current Assets Annual Cr 9,7249,835
    Total Assets Annual Cr 24,93421,601
    IndicatorMar 2023Mar 2022
    Book Value Per Share Annual Rs 306292
    ROE Annual % 78
    ROCE Annual % 910
    Total Debt to Total Equity Annual --
    EBDIT Annual Margin % 1719
    IndicatorSep 2023Jun 2023Mar 2023Dec 2022Sep 2022Jun 2022Mar 2022
    Oper Rev Qtr Cr 7,1516,7916,3796,3885,6746,1775,795
    Operating Expenses Qtr Cr 5,8465,6995,4715,4534,9495,2994,835
    Operating Profit Qtr Cr 1,3731,1511,002954791936974
    Depreciation Qtr Cr 418327346321298280254
    Interest Qtr Cr 6857564525159
    Tax Qtr Cr 32424222418911315917
    Net Profit Qtr Cr 757571506491409521576
    IndicatorMar 2023Mar 2022
    Total Revenue Annual Cr 25,14623,776
    Operating Expenses Annual Cr 21,13719,069
    Operating Profit Annual in Cr 3,7194,387
    Depreciation Cr 1,2451,127
    Interest Annual Cr 14049
    Tax Annual Cr 685726
    Net Profit Annual Cr 1,9282,648
    IndicatorMar 2023Mar 2022
    Cash from Operating Activity Annual Cr 2,3875,016
    Cash from Investing Activity Annual Cr -3,978-3,212
    Cash from Financing Annual Activity Cr 1,814-2,969
    Net Cash Flow Annual Cr 223-1,164
    IndicatorMar 2023Mar 2022
    Total ShareHolders Funds Annual Cr 26,84024,576
    Fixed Assets Annual Cr 15,81813,804
    Total Non Current Assets Annual Cr 18,34415,799
    Total Current Assets Annual Cr 21,54618,123
    Total Assets Annual Cr 39,89033,922
    IndicatorMar 2023Mar 2022
    Book Value Per Share Annual Rs 458419
    ROE Annual % 711
    ROCE Annual % 1014
    Total Debt to Total Equity Annual --
    EBDIT Annual Margin % 1620
    Invest in Aurobindo Pharma

    Aurobindo Pharma Technicals

    EMA & SMA

    Current Price
    ₹1,021.5
    0.05 (0%)
    pointer
    • Bullish Moving Average
    • ___
    • 14
    • Bearish Moving Average
    • ___
    • 2
    • 20 Day
    • ₹978.41
    • 50 Day
    • ₹926.19
    • 100 Day
    • ₹862.57
    • 200 Day
    • ₹770.18
    • 20 Day
    • ₹965.14
    • 50 Day
    • ₹917.36
    • 100 Day
    • ₹869.71
    • 200 Day
    • ₹720.60

    Aurobindo Pharma Resistance and Support

    PIVOT
    ₹1,021.12
    Resistance
    First Resistance 1,032.23
    Second Resistance 1,043.02
    Third Resistance 1,054.13
    RSI 65.52
    MFI 78.21
    MACD Single Line 33.74
    MACD 37.74
    Support
    First Resistance 1,010.33
    Second Resistance 999.22
    Third Resistance 988.43

    Aurobindo Pharma Delivery and Volume

    Period NSE + BSE Volume Avg NSE + BSE Delivery Volume Avg NSE + BSE Delivery Volume %
    Day 2,448,245 128,998,029 52.69
    Week 2,033,576 100,641,651 49.49
    1 Month 2,457,904 96,472,730 39.25
    6 Month 2,123,843 85,633,366 40.32

    Aurobindo Pharma Result Highlights

    Aurobindo Pharma Synopsis

    NSE-Medical-Generic Drugs

    Aurobindo Pharma is involved in the business activities of Manufacture of medicinal substances used in the manufacture of pharmaceuticals: antibiotics, endocrine products, basic vitamins; opium derivatives; sulpha drugs; serums and plasmas; salicylic acid, its salts and esters; glycosides and vegetable alkaloids; chemically pure suger etc.. Company’s Total Operating Revenue is Rs. 12792.28 Cr. and Equity Capital is Rs. 58.59 Cr. for the Year ended 31/03/2023. Aurobindo Pharma Ltd. is a Public Limited Listed company incorporated on 26/12/1986 and has its registered office in the State of Telangana, India. Company’s Corporate Identification Number(CIN) is L24239TG1986PLC015190 and registration number is 015190.
    Market Cap 59,851
    Sales 12,039
    Shares in Float 28.12
    No of funds 708
    Yield 0.59
    Book Value 3.34
    U/D Vol ratio 1.3
    LTDebt / Equity
    Alpha 0.31
    Beta 0.53

    Aurobindo Pharma

    Owner NameSep-23Jun-23Mar-23Dec-22
    Promoters 51.83%51.83%51.83%51.83%
    Mutual Funds 11.27%8.37%7.64%7.5%
    Insurance Companies 6.67%7.03%7.2%7.15%
    Foreign Portfolio Investors 22.45%24.12%23.03%22.31%
    Financial Institutions/ Banks
    Individual Investors 6.16%7.02%8.54%9.42%
    Others 1.62%1.63%1.76%1.79%

    Aurobindo Pharma Management

    Name Designation
    Mr. K Ragunathan Non Executive Chairman
    Mr. K Nithyananda Reddy Vice Chairman & Mng.Director
    Mr. P Sarath Chandra Reddy Whole Time Director
    Dr. M Sivakumaran Whole Time Director
    Mr. M Madan Mohan Reddy Whole Time Director
    Mr. P V Ramprasad Reddy Non Executive Director
    Mrs. Savita Mahajan Ind. Non-Executive Director
    Mr. Girish P Vanvari Ind. Non-Executive Director
    Dr.(Mrs.) Avnit Bimal Singh Ind. Non-Executive Director

    Aurobindo Pharma Forecast

    Price Estimates

    2,000(9.8%)
    1,758(-3.5%)
    1,590(-12.7%)

    Other Analyst Rating

    Aurobindo Pharma Corporate Action

    Date Purpose Remarks
    2023-11-09 Quarterly Results & Interim Dividend
    2023-08-12 Quarterly Results
    2023-05-27 Audited Results
    2023-02-09 Quarterly Results & Interim Dividend
    2022-11-12 Quarterly Results
    Date Purpose Remarks
    2023-11-20 INTERIM Rs.3.00 per share(300%)First Interim Dividend
    2023-02-17 INTERIM Rs.3.00 per share(300%)Interim Dividend
    2022-06-07 INTERIM Rs.4.50 per share (450%) Fourth Interim Dividend
    2022-02-21 INTERIM Rs.1.50 per share(150%)Third Interim Dividend
    2021-11-18 INTERIM Rs.1.50 per share (150%) Second Interim Dividend

    Aurobindo Pharma MF Shareholding

    Name Amount(cr)
    HDFC Balanced Advantage Fund Growth 63,981
    HDFC Mid-Cap Opportunities Fund Growth 47,846
    ICICI Prudential Value Discovery Fund Growth 32,494
    Kotak Equity Arbitrage Fund Growth 28,958
    Mirae Asset Emerging Bluechip Fund Growth 28,104

    Aurobindo Pharma FAQs

    What is Share Price of Aurobindo Pharma ?

    Aurobindo Pharma share price is ₹1,021 As on 30 November, 2023 | 08:58

    What is the Market Cap of Aurobindo Pharma ?

    The Market Cap of Aurobindo Pharma is ₹59853.6 Cr As on 30 November, 2023 | 08:58

    What is the P/E ratio of Aurobindo Pharma ?

    The P/E ratio of Aurobindo Pharma is 25.7 As on 30 November, 2023 | 08:58

    What is the PB ratio of Aurobindo Pharma ?

    The PB ratio of Aurobindo Pharma is 2.2 As on 30 November, 2023 | 08:58

    Is it a good time to invest in Aurobindo Pharma?

    Aurobindo Pharma has an operating revenue of Rs.24,010.31 Cr. on a trailing 12-month basis. An annual revenue growth of 8% is good, Pre-tax margin of 30% is great. Many brokers and analysts have recommended 'Buy' on the stock.

    How many times have Aurobindo Pharma given dividends since 2000?

    Aurobindo Pharma Ltd. has declared 40 dividends since May 10, 2000.

    What is the stock price CAGR of Aurobindo Pharma?

    The stock price CAGR of Aurobindo Pharma for 10 Years is 30%, 5 Years is 0%, 3 Years is -3%, 1 Year is -25%.

    What is the ROE of Aurobindo Pharma?

    Aurobindo Pharma has an ROE of 24% which is exceptional.

    What is Aurobindo Pharma’s debt to equity?

    Aurobindo Pharma has a reasonable debt to equity of 1%, which signals a healthy balance sheet.

    Q2FY23

    More Information

    CIN: L67190MH2007PLC289249 | Stock Broker SEBI Regn.: INZ000010231 | SEBI RA Regn.: INH000004680 | SEBI Depository Regn.: IN DP CDSL: IN-DP-192-2016 | AMFI REGN No.: ARN-104096 | NSE Member id: 14300 | BSE Member id: 6363 | MCX Member ID: 55945 | Investment Adviser Regn No: INA000014252 | Registered Address - IIFL House, Sun Infotech Park, Road no. 16V, Plot no. B-23, MIDC, Thane Industrial Area, Waghle Estate, Thane, Maharashtra - 400604

    *Brokerage will be levied flat fee/executed order basis and not on a percentage basis. Flat fee of Rs. 10/order is available with Power Investor & Ultra Trader Packs. Investment in securities market are subject to market risk, read all related documents carefully before investing. Digital account would be opened after all procedure relating to IPV and client due diligence is completed. If sale/ purchase value of share of Rs.10/- or less, a maximum brokerage of 25 paisa per share may be collected. Brokerage will not exceed the SEBI prescribed limit.

    Compliance Officer: Ms. Namita Godbole, Email: support@5paisa.com, Support desk helpline: 8976689766

    Contact Us

    Attention Investors

    • 1. No need to issue cheques by investors while subscribing to IPO. Just write the bank account number and sign in the application form to authorise your bank to make payment in case of allotment. No worries for refund as the money remains in investor's account.
    • 2. Message from Exchange(s): Prevent Unauthorised transactions in your account --> Update your mobile numbers/email IDs with your stock brokers. Receive information of your transactions directly from Exchange on your mobile/email at the end of the day. Issued in the interest of investors.
    • 3. Message from Depositories: a) Prevent Unauthorized Transactions in your demat account --> Update your mobile number with your Depository Participant. Receive alerts on your registered mobile for all debit and other important transactions in your demat account directly from CDSL on the same day issued in the interest of investors. b) KYC is one time exercise while dealing in securities markets - once KYC is done through a SEBI registered intermediary (broker, DP, Mutual Fund etc.), you need not undergo the same process again when you approach another intermediary.
    ©2023, 5Paisa Capital Ltd. All Rights Reserved.
    We are ISO 27001:2013 Certified.